Correlation Between NYSE Composite and Entera Bio
Can any of the company-specific risk be diversified away by investing in both NYSE Composite and Entera Bio at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining NYSE Composite and Entera Bio into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between NYSE Composite and Entera Bio, you can compare the effects of market volatilities on NYSE Composite and Entera Bio and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in NYSE Composite with a short position of Entera Bio. Check out your portfolio center. Please also check ongoing floating volatility patterns of NYSE Composite and Entera Bio.
Diversification Opportunities for NYSE Composite and Entera Bio
0.0 | Correlation Coefficient |
Pay attention - limited upside
The 3 months correlation between NYSE and Entera is 0.0. Overlapping area represents the amount of risk that can be diversified away by holding NYSE Composite and Entera Bio in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Entera Bio and NYSE Composite is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on NYSE Composite are associated (or correlated) with Entera Bio. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Entera Bio has no effect on the direction of NYSE Composite i.e., NYSE Composite and Entera Bio go up and down completely randomly.
Pair Corralation between NYSE Composite and Entera Bio
If you would invest 1,907,793 in NYSE Composite on December 30, 2024 and sell it today you would earn a total of 19,237 from holding NYSE Composite or generate 1.01% return on investment over 90 days.
Time Period | 3 Months [change] |
Direction | Flat |
Strength | Insignificant |
Accuracy | 0.0% |
Values | Daily Returns |
NYSE Composite vs. Entera Bio
Performance |
Timeline |
NYSE Composite and Entera Bio Volatility Contrast
Predicted Return Density |
Returns |
NYSE Composite
Pair trading matchups for NYSE Composite
Pair Trading with NYSE Composite and Entera Bio
The main advantage of trading using opposite NYSE Composite and Entera Bio positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if NYSE Composite position performs unexpectedly, Entera Bio can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Entera Bio will offset losses from the drop in Entera Bio's long position.NYSE Composite vs. Corby Spirit and | NYSE Composite vs. Church Dwight | NYSE Composite vs. Nascent Wine | NYSE Composite vs. Crocs Inc |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Other Complementary Tools
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Fundamental Analysis View fundamental data based on most recent published financial statements |